Pharmaceutical compositions comprising adherent stromal cells (ASCs) are provided. The ASCs are obtained from at least two donors. Articles of manufacture comprising the pharmaceutical compositions together with a delivery device for administering the ASCs to a subject are also provided. Also provided are methods of treating various diseases and conditions that are treatable by administering ASCs to a subject in need of treatment.

This invention relates to a tissue construct comprising a core portion having a recess and composed of fibrous connective tissue, and loose fibrous somatic stem cell-accumulated tissue comprising type III collagen and somatic stem cells which is formed in the recess; a device for producing the same; and a method for collecting somatic stem cells from the tissue construct.

A composition including, (a) a mineral particle, (b) endothelial cells and mesenchymal cells, and (3) hyaluronic acid, is provided. Moreover, a kit which includes: a syringe, a mineral particle covered with endothelial cells and mesenchymal cells organized in 2 or more cell layers attached to the mineral particle, and hyaluronic acid, is also provided. Last, a method for filling a gap in a bone of a subject in need thereof, including contacting the gap with a composition of: (a) a mineral particle, (b) endothelial cells and mesenchymal cells, and (3) hyaluronic acid is provided.

Closed disposable seeding systems with improved seeding chambers permitting uniform seeding of a scaffold or graft with patient's cells are provided. The seeding chambers with a variable width along the length of the chamber, or a minimal gap between the scaffold and chamber wall, provide an improvement of the prior seeding chambers of closed disposable seeding systems by providing faster and more efficient and uniform seeding of the grafts and scaffolds. Also described are scaffolds with biomechanical and structural properties permitting spontaneous reversal of stenosis and neotissue formation as the graft degrades yielding a scaffold-free neovessel.

Various aspects of the present disclosure are directed toward devices, methods, and systems that include a reinforced biopolymer including a synthetic support membrane and a biopolymer. The reinforced biopolymer may have a measured optical transparency of at least 85%, a thickness of about 100 μm or less, and a toughness of at least 30 KJ/m.sup.3.

The present invention discloses bioengineered corneal grafts for treating either or both Keratoconus and visual impairment, selected from (i) a corneal Onlay comprises or coated by at least one member of Group A, consisting of biocompatible synthetic materials; at least one member of Group B, consisting of at least one type of biological polymer and optionally, at least one member of Group C, consisting of at least one type of protein and (ii) An intrastromal corneal lenticule graft, configured to mimic native corneal stroma tissue by means of its optical properties, mechanical properties, permeability and interaction with corneal stromal cells; wherein at least one portion of said lenticule comprises or coated by at least one member of Group D, consisting of transparent crosslinked hydrogel; at least one member of Group E, consisting of collagen; collagen methacrylate, recombinant mammal collagen, mammal-sourced collagen; and optionally, at least one member of Group F, consisting of Keratocytes and/or stem cells and any combination thereof. The present invention further discloses compositions, methods for production, implementation and treatment of medical indications by aforesaid corneal graft.

Provided is a method for freezing a cell aggregate including neural cells. provided is a method for freezing a cell aggregate including neural cells and having a three-dimensional structure, which comprises following steps (1) and (2): (1) contacting a cell aggregate including neural cells and having a three-dimensional structure with a preservation solution at 0° C. to 30° C. prior to freezing to prepare a preservation solution-soaked cell aggregate; and (2) cooling the preservation solution-soaked cell aggregate obtained in step (1) from a temperature at least about 5° C. higher than the freezing point of the preservation solution to a temperature about 5° C. lower than the freezing point at an average cooling speed of 2 to 7° C./min to freeze the cell aggregate.

A method includes forming a scaffold and seeding the scaffold with live cells; growing the cells in the scaffold; and 3D printing the cells into a living subject, where the cells continue to live in the living subject.

A sheet structure comprising two joined extracellular matrix (ECM) tissue or sheet layers and a physiological sensor disposed therebetween; the ECM tissue being derived from a mammalian tissue source that includes small intestine submucosa (SIS), urinary bladder submucosa (UBS), stomach submucosa (SS), urinary basement membrane (UBM), liver basement membrane (LBM), amniotic membrane, mesothelial tissue, placental tissue and cardiac tissue.

Provided herein is a 3D printing system and related compositions, and method of using such, that can produce a polymeric microfiber having embedded microspheres encapsulating an active agent with micron precision and high spatial and temporal resolution.